Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Dow
Johnson and Johnson
Mallinckrodt
Colorcon

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

SUPRAX Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Suprax patents expire, and when can generic versions of Suprax launch?

Suprax is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms. and is included in eight NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefixime profile page.

Drug patent expirations by year for SUPRAX
Drug Prices for SUPRAX

See drug prices for SUPRAX

Recent Clinical Trials for SUPRAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AIDS Healthcare FoundationPhase 2
University of California, Los AngelesPhase 2
University of Colorado, DenverPhase 1

See all SUPRAX clinical trials

Pharmacology for SUPRAX
Synonyms for SUPRAX
(-)-Cefixim
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime) trihydrate
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime)trihydrate
(6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b
(6R,7R)-7-[-2-(2-Amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4. 2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(6R,7R)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
214265-67-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6R-(6alpha,7beta(Z)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6R,7R)-
50C371
79350-37-1
7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
AB00513842
AB0073052
AC-4350
AC1NSFNI
AKOS015854940
AKOS015961135
AT-7061
BC205782
BDBM84007
BPBio1_000622
BRD-K71059170-001-02-5
BRD-K71059170-001-08-2
BRN 6025058
BSPBio_000564
C04
C06881
CCG-220462
Cefixim
Cefixima
Cefixima [Spanish]
CEFIXIME
Cefixime (JAN/USP/INN)
Cefixime [USAN:USP:INN:BAN:JAN]
Cefixime Anhydrous
Cefixime EP Impurity C (Cefixime 7-epimer)
Cefixime, 98%
Cefixime, Antibiotic for Culture Media Use Only
Cefiximum
Cefiximum [Latin]
Cefixoral
Cefspan
Cephoral
CFIX
CHEBI:472657
CHEMBL1541
cid_5362065
CL 284,635
CL-284635
CS-4820
D00258
DB00671
Denvar
FK-027
FR- 17027
FR-17027
HMS2096M06
HMS2234J21
HMS3713M06
HY-B1381
LS-187248
MLS002222332
MolPort-003-845-687
NCGC00179521-01
Necopen
Prestwick3_000462
PubChem13762
RS0002
s4596
SCHEMBL24945
SMR001307271
SR-01000760706
SR-01000760706-4
Suprax (TN)
TC-070894
Tricef
UNII-XZ7BG04GJX
Unixime
X-2622
XZ7BG04GJX
ZINC12503147
Paragraph IV (Patent) Challenges for SUPRAX
Tradename Dosage Ingredient NDA Submissiondate
SUPRAX FOR SUSPENSION;ORAL cefixime 202091 2014-07-22

US Patents and Regulatory Information for SUPRAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd SUPRAX cefixime CAPSULE;ORAL 203195-001 Jun 1, 2012 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-002 Oct 25, 2010 RX No No   Start Trial   Start Trial   Start Trial
Lupin Pharms SUPRAX cefixime FOR SUSPENSION;ORAL 065129-001 Feb 23, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-003 Oct 25, 2010 RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Harvard Business School
AstraZeneca
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.